Compounds > spironolactone
Page last updated: 2024-08-17

spironolactone and mdv 3100

spironolactone has been researched along with mdv 3100 in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Chai, X; Chen, C; Cui, S; Hou, T; Hu, X; Li, D; Lou, S1
Arlt, W; Attard, G; Carreira, S; de Bono, JS; Goodall, J; Hay, CW; Lim, AC; McEwan, IJ; Nowakowska, K; Pezaro, C; Richards, J; Taylor, AE; Wingate, A1
Flynn, T; Guancial, EA; Kilari, D; Kilari, M1

Other Studies

3 other study(ies) available for spironolactone and mdv 3100

ArticleYear
Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1
    Journal of medicinal chemistry, 2022, 10-13, Volume: 65, Issue:19

    Topics: Acetamides; Androgen Antagonists; Androgen Receptor Antagonists; Cell Line, Tumor; Cell Proliferation; Humans; Ligands; Male; Prostatic Neoplasms; Pyrazoles; Receptors, Androgen

2022
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
    Cancer research, 2012, May-01, Volume: 72, Issue:9

    Topics: Androgen Receptor Antagonists; Androgens; Androstenes; Androstenols; Anilides; Benzamides; Binding, Competitive; Cell Line, Tumor; Drug Interactions; Eplerenone; Humans; Male; Metribolone; Nitriles; Phenylthiohydantoin; Prednisolone; Prostatic Neoplasms; Receptors, Androgen; Spironolactone; Tosyl Compounds

2012
Case Report: Spironolactone Withdrawal Associated With a Dramatic Response in a Patient With Metastatic Castrate-Resistant Prostate Cancer.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:1

    Topics: Abiraterone Acetate; Benzamides; Drug Antagonism; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Spironolactone; Treatment Outcome

2017